Antihyperlipidemic Drugs Market

The global antihyperlipidemic drugs market accounted for $9,456 million in 2018, and is expected to reach $16,865 million by 2026, registering a CAGR of 7.5% from 2019 to 2026. 

Lipids are chemical substances that are insoluble in water such as cholesterol and triglycerides. Hyperlipidemia is a medical condition marked by elevation of lipid level in the blood. This rise in lipid levels leads to increase in fatty deposits in arteries, which cause blockages in the arteries of the patient. The blockages can in turn lead to rise in risk related to heart attacks. Therefore, hyperlipidemia is a major medical condition that requires treatment. The drugs that are used to treat hyperlipidemia are called as antihyperlipidemic drugs. Some of the drugs available in the market include bile acid, sequestrants, cholesterol absorption inhibitors, and others.  

The factors that contribute for the growth of the market include surge in sedentary lifestyle. Furthermore, rise in incidence of disorders related to distributed cholesterol levels in the blood also contributes to the growth of the antihyperlipidemic drugs market. Moreover, surge in awareness regarding complications related with hyperlipidemia is another major factor that fuels the growth of the market. However, high cost of the treatment hinders the growth of the market. Conversely, growth opportunities exhibited by emerging economies is expected to offer lucrative opportunities during the forecast period.    

Antihyperlipidemic Drugs Market Segmentation  

The antihyperlipidemic drugs market size is studied based on segments, drug class and region to provide a detailed assessment of the market. Based on drug class, the market is divided into statins, pcsk9 inhibitors, bile acid sequestrants, cholesterol absorption inhibitors, fibric acid derivatives, and combination. Based on region, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, and rest of LAMEA). 

Segment Review

According to drug class, statins occupied the largest antihyperlipidemic drugs market share in 2018, owing to surge in the incidence of cardiovascular disorders. Furthermore, statins reduce the risk associated with heart attacks which is another major factor that contributes to the growth of the market. Moreover, PCSK9 inhibitors is expected to register the fastest growth during the forecast period, owing to the benefits offered such as drastic reduction of LDL levels in the blood. The other factors that boost the antihyperlipidemic drugs market growth include the surge in the geriatric population and rise in healthcare expenditure across the globe. In addition, the other factors which boost the growth of the market include the additional benefits offered by the statins such as improved endothelial function, enhance the stability of atherosclerotic plaques, and reduce the amount of inflammation & damage done to cells due to oxidative stress.

By region, North America accounted for the major antihyperlipidemic drugs market share in 2018, and is expected to continue this trend due to easy availability of the antihyperlipidemic drugs. Moreover, surge in sedentary lifestyle in the region is another major factor that contributes to the growth of the market. Furthermore, surge in the obese population is another major factor that fuels the growth of the antihyperlipidemic drugs market. In addition, the presence of major key players such as Abbvie Inc., Amgen Inc., Bristol-Myers Squibb Company, Merck & Co., Inc. and others is another major factor that fuels the growth of antihyperlipidemic drugs market in the region. On the other side, Asia-Pacific is estimated to register the fastest growth during the forecast period, owing to surge in awareness related to the use of antihyperlipidemic drugs. The constantly evolving life science industry drives the growth of the market in the developing economies such as India, China, Malaysia, and others.

The global antihyperlipidemic drugs market is highly competitive and the prominent players in the market have adopted various strategies for garnering maximum market share. These include collaboration, product launch, partnership, and acquisition. Major players operating in the market include Boehringer Ingelheim GmbH, Merck KGaA, Johnson and Johnson, Bayer AG, Pfizer, Inc. Takeda Pharmaceutical Co., Ltd., AstraZeneca plc, Daiichi Sankyo Company, Sanofi S.A., and Novartis International AG.

Key Benefits for Stakeholders:

• This report entails a detailed quantitative analysis along with the current global antihyperlipidemic drugs market trends from 2019 to 2026 to identify the prevailing opportunities along with the strategic assessment.
• The antihyperlipidemic drugs market forecast is studied from 2019 to 2026. 
• The market size and estimations are based on a comprehensive analysis of key developments in the industry. 
• A qualitative analysis based on innovative products facilitates strategic business planning.
• The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market

 Antihyperlipidemic Drugs Market Report Highlights